source
- Artiva to quit autoimmune cell therapy work, cut staff after patient deathsThe disclosure makes Artiva the third company to recently report fatal events in an autoimmune cell therapy trial, following announcements from Novartis and Bristol Myers Squibb.BioPharma Dive · 13d ago↗ source
- Melanoma vaccine shows 42% risk reduction at ESMO 2026, but shares tumble on early data releaseModerna and Merck presented Phase 3 results for their melanoma vaccine intismeran autogene at the European Society for Medical Oncology meeting. The trial reported a 42% reduction in the relative r…